Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy

被引:0
|
作者
Hartrampf, Philipp E. [1 ]
Mihatsch, Patrick W. [2 ]
Seitz, Anna Katharina [3 ]
Solnes, Lilja B. [4 ]
Rowe, Steven P. [4 ]
Pomper, Martin G. [4 ]
Kuebler, Hubert [3 ]
Bley, Thorsten A. [2 ]
Buck, Andreas K. [1 ]
Werner, Rudolf A. [1 ,4 ]
机构
[1] Univ Hosp Wurzburg, Dept Nucl Med, Wurzburg, Germany
[2] Univ Hosp Wurzburg, Dept Diagnost & Intervent Radiol, Wurzburg, Germany
[3] Univ Hosp Wurzburg, Dept Urol & Paediat Urol, Wurzburg, Germany
[4] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD USA
关键词
PSMA; prostate cancer; radioligand therapy; overall survival; body composition; ANDROGEN-DEPRIVATION THERAPY; CLINICAL-OUTCOMES; OPEN-LABEL; MEN; FAT; CHEMOTHERAPY; MITOXANTRONE; CABAZITAXEL; ABIRATERONE; PREDNISONE;
D O I
10.2967/jnumed.122.265379
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In patients with prostate cancer scheduled for systemic treatment, being overweight is linked to prolonged overall survival (OS), whereas sarcopenia is associated with shorter OS. We investigated fat-related and body composition parameters in patients undergoing prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) to assess their predictive value for OS. Methods: Body mass index (BMI, in kg/m(2)) and CT-derived body composition parameters (total, subcutaneous, visceral fat area, and psoas muscle area at the L3-L4 level) were determined for 171 patients scheduled for PSMA-directed RLT. After normalization for stature, the psoas muscle index was used to define sarcopenia. Outcome analysis was performed using Kaplan-Meier curves and Cox regression including fat-related and other clinical parameters (Gleason score, C-reactive protein [CRP], lactate dehydrogenase [LDH], hemoglobin, and prostate-specific antigen levels). The Harrell C-index was used for goodness-of-fit analysis. Results: Sixty-five patients (38%) had sarcopenia, and 98 patients (57.3%) had increased BMI. Relative to the 8-mo OS in normal-weight men (BMI < 25), overweight men (25 = BMI > 30) and obese men (BMI =30) achieved a longer OS of 14 mo (hazard ratio [HR], 0.63; 95% CI, 0.40-0.99; P = 0.03) and 13 mo (HR, 0.47; 95% CI, 0.29-0.77; P = 0.004), respectively. Sarcopenia showed no impact on OS (11 vs. 12 mo; HR, 1.4; 95% CI, 0.91-2.1; P = 0.09). Most of the body composition parameters were tightly linked to OS on univari-able analyses, with the highest C-index for BMI. In multivariable analy-sis, a higher BMI (HR, 0.91; 95% CI, 0.86-0.97; P = 0.006), lower CRP (HR, 1.09; 95% CI, 1.03-1.14; P < 0.001), lower LDH (HR, 1.08; 95% CI, 1.03-1.14; P < 0.001), and longer interval between initial diagnosis and RLT (HR, 0.95; 95% CI, 0.91-0.99; P = 0.02) were significant pre-dictors of OS. Conclusion: Increased fat reserves assessed by BMI, CRP, LDH, and interval between initial diagnosis and RLT, but not CT-derived body composition parameters, were relevant predictors for OS. As BMI can be altered, future research should investigate whether a high-calorie diet before or during PSMA RLT may improve OS.
引用
收藏
页码:1272 / 1278
页数:7
相关论文
共 50 条
  • [21] Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen
    Kai Huang
    Imke Schatka
    Julian M. M. Rogasch
    Randall L. Lindquist
    Maria De Santis
    Barbara Erber
    Piotr Radojewski
    Winfried Brenner
    Holger Amthauer
    Annals of Nuclear Medicine, 2021, 35 : 314 - 320
  • [22] Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen
    Huang, Kai
    Schatka, Imke
    Rogasch, Julian M. M.
    Lindquist, Randall L.
    De Santis, Maria
    Erber, Barbara
    Radojewski, Piotr
    Brenner, Winfried
    Amthauer, Holger
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (03) : 314 - 320
  • [23] Prostate-specific antigen response with enzalutamide in nonmetastatic castration-resistant prostate cancer: PROSPER
    von Bueren, Moritz
    Sternberg, N.
    Fizazi, Karim
    Saad, Fred
    Rathenborg, Per
    Shore, Neal D.
    Demirhan, Eren
    Modelska, Katharina
    De Phung
    Krivoshik, Andrew
    Hussain, Maha
    SWISS MEDICAL WEEKLY, 2019, 149 : 16S - 17S
  • [24] Relationship between abiraterone exposure, prostate-specific antigen (PSA) kinetics, and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Xu, Steven
    Ryan, Charles J.
    Stuyckens, Kim
    Smith, Matthew R.
    Saad, Fred
    Griffin, Thomas W.
    Park, Youn Choi
    Yu, Margaret K.
    Vermeulen, An
    Poggesi, Italo
    Nandy, Partha
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [25] Prostate-specific membrane antigen PET/CT-guided, metastasis-directed radiotherapy for oligometastatic castration-resistant prostate cancer
    Nikitas, John
    Castellanos, Angela
    Farolfi, Andrea
    Seyedroudbari, Ameen
    Kishan, Amar Upadhyaya
    Nickols, Nicholas George
    Steinberg, Michael L.
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
    Nikitas, John
    Rieger, Angela Castellanos
    Farolfi, Andrea
    Kishan, Amar
    Nickols, Nicholas
    Steinberg, Michael
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [27] Phase I trial of the prostate-specific membrane antigen directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
    Galsky, Matthew D.
    Eisenberger, Mario
    Moore-Cooper, Sandra
    Kelly, W. Kevin
    Slovin, Susan F.
    DeLaCruz, Anthony
    Lee, Yih
    Webb, Iain J.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2147 - 2154
  • [28] Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
    Fendler, Wolfgang P.
    Weber, Manuel
    Iravani, Amir
    Hofman, Michael S.
    Calais, Jeremie
    Czernin, Johannes
    Ilhan, Harun
    Saad, Fred
    Small, Eric J.
    Smith, Matthew R.
    Perez, Paola M.
    Hope, Thomas A.
    Rauscher, Isabel
    Londhe, Anil
    Lopez-Gitlitz, Angela
    Cheng, Shinta
    Maurer, Tobias
    Herrmann, Ken
    Eiber, Matthias
    Hadaschik, Boris
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7448 - 7454
  • [29] Prostate-specific membrane antigen-directed nanoparticle targeting for extreme nearfield ablation of prostate cancer cells
    Lee, Seung S.
    Roche, Philip J. R.
    Giannopoulos, Paresa N.
    Mitmaker, Elliot J.
    Tamilia, Michael
    Paliouras, Miltiadis
    Trifiro, Mark A.
    TUMOR BIOLOGY, 2017, 39 (03)
  • [30] Prostate-specific membrane antigen expression on positron emission tomography/computed tomography in patients with metastatic castration-resistant prostate cancer
    Calderoni, L.
    Maietti, E.
    Farolfi, A.
    Mei, R.
    Louie, K.
    Groaning, M.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S407 - S407